Astrid A M Van Der Veldt

List of Publications by Year
in descending order

66 papers	1,533 citations	566801 15 h-index	395343 33 g-index
69 all docs	69 docs citations	69 times ranked	2309 citing authors

#	Article	IF	Citations
1	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature Medicine, 2022, 28, 1178-1188.	15.2	121
2	Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patientsâ€™ perspective. European Journal of Cancer, 2020, 136, 132-139.	1.3	120
3	mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncology, The, 2021, 22, 1681-1691.	5.1	118
4	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1â€“Treated Patients in the Dutch Melanoma Treatment Registry. Clinical Cancer Research, 2020, 26, 2268-2274.	3.2	112
5	Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. European Urology, 2017, 72, 411-423.	0.9	89
6	Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. Journal of Clinical Oncology, 2019, 37, 3142-3151.	0.8	83
7	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. European Journal of Cancer, 2020, 141, 171-184.	1.3	65
8	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. , 2019, 7, 192.		60
9	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. Thyroid, 2020, 30, 966-973.	2.4	57
10	First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. Journal of Clinical Oncology, 2020, 38, 10002-10002.	0.8	57
11	Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1931-1939.	3.3	53
12	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. British Journal of Cancer, 2018, 118, 1296-1301.	2.9	49
13	CD45RA+CCR7â^' CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab. , 2019, 7, 149.		44
14	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. , 2020, 8, e000586.		39
15	Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. , 2019, 7, 182.		29
16	Realâ€world outcomes of advanced melanoma patients not represented in phase <scp>III</scp> trials. International Journal of Cancer, 2020, 147, 3461-3470.	2.3	27
17	Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. BMC Cancer, 2021, 21, 323.	1.1	22
18	The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.. Journal of Clinical Oncology, 2022, 40, TPS9605-TPS9605.	0.8	19

#	Article	IF	Citations
19	Biomarker-Oriented Therapy in Bladder and Renal Cancer. International Journal of Molecular Sciences, 2021, 22, 2832.	1.8	18
20	The unfavorable effects of <scp>COVID</scp>â€19 on Dutch advanced melanoma care. International Journal of Cancer, 2022, 150, 816-824.	2.3	18
21	Brain metastases: the role of clinical imaging. British Journal of Radiology, 2022, 95, 20210944.	1.0	18
22	Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. Lancet Oncology, The, 2022, 23, 833-835.	5.1	18
23	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. Cancers, 2020, 12, 2072.	1.7	16
24	First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. British Journal of Cancer, 2021, 124, 1222-1230.	2.9	16
25	Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. European Journal of Cancer, 2021, 144, 242-251.	1.3	16
26	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. Journal of Clinical Oncology, 2019, 37, TPS9605-TPS9605.	0.8	16
27	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers, 2020, 12, 1003.	1.7	15
28	Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma. British Journal of Dermatology, 2022, 187, 381-391.	1.4	14
29	Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. Clinical Genitourinary Cancer, 2021, 19, 274.e1-274.e16.	0.9	12
30	Primary Melanoma Characteristics of Metastatic Disease: A Nationwide Cancer Registry Study. Cancers, 2021, 13, 4431.	1.7	12
31	Discontinuation of <scp>antiâ€PD</scp>â€1 monotherapy in advanced melanomaâ€”Outcomes of daily clinical practice. International Journal of Cancer, 2022, 150, 317-326.	2.3	12
32	Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. Journal of Clinical Oncology, 2022, 40, 9501-9501.	0.8	12
33	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. Cancers, 2020, 12, 1176.	1.7	11
34	68Ga-PSMAâ€“Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 1607-1614.	2.8	11
35	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. Cancers, 2021, 13, 2826.	1.7	11
36	Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. ESMO Open, 2021, 6, 100320.	2.0	10

#	Article	IF	Citations
37	Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. Cancers, 2021, 13, 1370.	1.7	9
38	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. Cancers, 2021, 13, 4639.	1.7	9
39	Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage Iâ€“II Melanoma Patients at Risk of Disease Relapse. Cancers, 2022, 14, 2854.	1.7	9
40	Genomeâ€wide aneuploidy detected by mFastâ€SeqS in circulating cellâ€free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer. Molecular Oncology, 2022, 16, 2086-2097.	2.1	8
41	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. European Journal of Cancer, 2022, 160, 261-272.	1.3	7
42	Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation. ESMO Open, 2021, 6, 100303.	2.0	7
43	Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. Melanoma Research, 2022, 32, 460-468.	0.6	7
44	Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition. Frontiers in Immunology, 2021, 12, 627186.	2.2	6
45	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. Cancer Immunology, Immunotherapy, 2021, 70, 3123-3135.	2.0	6
46	Antiâ€“PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells. Clinical Cancer Research, 2022, 28, 215-226.	3.2	5
47	Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium. Neuro-Oncology, 2022, 24, 326-328.	0.6	5
48	Anti-PD-1: When to Stop Treatment. Current Oncology Reports, 2022, 24, 905-915.	1.8	5
49	The BRAF P.V600E Mutation Status of Melanoma Lung Metastases Cannot Be Discriminated on Computed Tomography by LIDC Criteria nor Radiomics Using Machine Learning. Journal of Personalized Medicine, 2021, 11, 257.	1.1	4
50	Assessment of imaging biomarkers in the follow-up of brain metastases after SRS. Neuro-Oncology, 2021, 23, 1983-1984.	0.6	4
51	Early response marker during pembrolizumab treatment in metastatic urothelial cancer: Temporal shift in peripheral CD4 T cells expressing chemokine receptors.. Journal of Clinical Oncology, 2020, 38, 5033-5033.	0.8	2
52	Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography. Journal of Personalized Medicine, 2022, 12, 726.	1.1	2
53	Author's reply to: The realâ€world outcome of metastatic melanoma: Unknown primary vs. known cutaneous. International Journal of Cancer, 2019, 145, 3175-3176.	2.3	1
54	Nivolumab plus ipilimumab as neoadjuvant treatment in primary advanced renal cell tumors: Cutting edges for cutting-edge surgery. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 553-554.	0.8	1

#	Article	IF	Citations
55	False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (Tâ€VEC). Journal of Surgical Oncology, 2021, 124, 1161-1165.	0.8	1
56	Survival of stage IV melanoma in Belgium and the Netherlands. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	1
57	Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers, 2021, 13, 5077.	1.7	1
58	Correlation between nivolumab exposure and treatment outcome in NSCLC.. Journal of Clinical Oncology, 2018, 36, 9057-9057.	0.8	1
59	Mesenchymal-epithelial transition factor (MET) immunoreactivity in positive sentinel nodes from patients with melanoma. Annals of Diagnostic Pathology, 2022, 58, 151909.	0.6	1
60	Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151â€“6. European Urology, 2020, 77, e76-e77.	0.9	0
61	Remarkable Healthy Cohort of Patients With Cancer. Journal of Clinical Oncology, 2021, 39, 1092-1093.	0.8	0
62	Efficacy of checkpoint inhibition in advanced acral melanoma.. Journal of Clinical Oncology, 2021, 39, e21527-e21527.	0.8	0
63	Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients.. Journal of Clinical Oncology, 2018, 36, e21239-e21239.	0.8	0
64	Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy.. Journal of Clinical Oncology, 2020, 38, 10032-10032.	0.8	0
65	Management of checkpoint inhibitor toxicity and survival in patients with advanced melanoma.. Journal of Clinical Oncology, 2022, 40, 9546-9546.	0.8	0
66	Adjuvant treatment of in-transit melanoma: Addressing the knowledge gap left by clinical trials.. Journal of Clinical Oncology, 2022, 40, 9577-9577.	0.8	0